title: Effects of helicobacter pylori eradication on chronic nonspecific pharyngeal symptoms.
abstract: OBJECTIVE
  Although its pathophysiology is not obvious, the discussion on chronic nonspecific pharyngeal symptoms encompasses a broad range of various factors, such as nasal obstruction, extraesophageal reflux disease, some of the chronic upper respiratory infections, and allergy. We found a high seroprevalence of Helicobacter pylori in a group of selected patients with no possible conditions responsible for complaints. To show a possible role of H. pylori infection in chronic pharyngeal complaints, we investigated symptomatic response following eradication therapy.
  
  
  METHODS
  In a prospective cohort study, 72 subjects with H. pylori seropositivity had their symptoms measured by a questionnaire before and 3 months following H. pylori eradication therapy. The symptomatic response was compared between eradicated and noneradicated groups 3 months after eradication therapy.
  
  
  RESULTS
  In 39 of 72 patients H. pylori was eradicated successfully. Mann-Whitney U analysis showed the pharyngeal symptom improvement rate, measured using the absolute difference in symptom score. For two major symptoms (chronic throat irritation, sore throat), it was significantly lower for H. pylori-noneradicated cases than for H. pylori-eradicated cases (p = .003 and p < .001, respectively).
  
  
  CONCLUSIONS
  Resolution of the symptoms in the eradicated group suggests that H. pylori has a role in developing chronic nonspecific pharyngeal symptoms. These data may be important for future treatment strategies for this disease.
authors.affiliation: Department of Otorhinolaryngology, Gaziosmanpasa University Medical Faculty, Tokat, Turkey. ibrahimal@hotmail.com
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Aladag
authors.forename: Ahmet
authors.initials: A
authors.lastname: Eyibilen
authors.forename: Mehmet
authors.initials: M
authors.lastname: Guven
authors.forename: Unal
authors.initials: U
authors.lastname: Erkokmaz
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001944:Breath Tests; D002908:Chronic Disease; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D017060:Patient Satisfaction; D010608:Pharyngeal Diseases / Q000209:etiology* / Q000503:physiopathology; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D009853:Omeprazole